Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRx0237 in mild Alzheimer's disease
NCT01689233Phase 3Completed
- Sponsor
- TauRx Therapeutics Ltd
- Start
- Oct 2012
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of hydromethylthionine mesylate in Alzheimer's disease (AD), sponsored by TauRx Therapeutics Ltd. Started Oct 2012; status: completed.
02
Drugs
hydromethylthionine mesylate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01689233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01689233.